超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

澳大利亞Benitec
Benitec Co. Ltd.是澳大利亞上市公司，世界上小核酸技術研發的先驅，擁有多項技術專利。許多醫藥界的巨頭，如默克，輝瑞等公司都購買了他們的專利使用權。Benitec致力于利用小核酸基因沉默技術開發治療人類重大疾病如艾滋病、癌癥及肝炎藥物的研究。其中與洛杉磯希望之城生物醫學和遺傳學中心共同開發的治療艾滋病的小核酸干擾藥物已經在美國FDA獲準進入I期臨床試驗階段。

Benitec Ltd is a biotechnology company listed on the Australian Stock Exchange (ASX: BLT). Founded in 1997 to commercialise research from Queensland's Department of Primary Industries (DPI), Benitec is one of the pioneers of RNA interference (RNAi) technology, which can be used to precisely destroy RNA viruses and silence the expression of defective genes. Benitec's ongoing goal is to generate value through the commercialisation of ddRNAi in the area of human therapeutics.

The vision is for Benitec to be an internationally competitive company dedicated to the development of treatments for serious human diseases including infectious diseases, neurological disorders, cancer and autoimmune diseases, through leadership in RNAi technologies and strategic partnerships with leading biopharmaceutical companies and research organisations globally.